Health Care • Biotechnology: Pharmaceutical Preparations
$18.29 ▼ -0.47
(-2.50%)
MKT CAP: $2.16B • VOL: 877.9K
52W L $15 52W H $30
IMNM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $6.9M | $9.0M | $14.0M |
| YoY Revenue Growth % | -23.2% | -35.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$224.1M | -$305.8M | -$109.5M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$212.4M | -$293.0M | -$106.8M |
| EBITDA (Normalized) | -$216.4M | -$300.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$190.9M | -$110.8M | -$7.6M |
| Capital Expenditures (CapEx) | $9.7M | $7.2M | — |
| Free Cash Flow (FCF) | -$200.6M | -$118.0M | -$7.6M |
| FCF Margin % | -80.0% | -80.0% | -54.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $653.5M | $143.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $634.3M | $181.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR IMNM.